NSE · VAISHALI
Vaishali Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹23 Cr with net profit ₹1 Cr — a 6.51% net margin, versus 1% the period before.
Shareholding
As of 2026-09-30
- Promoter31.61%
- Public68.39%
26,702 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.15× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #75 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Vaishali Pharma Limited(this company) | ₹91 Cr | 20.48 | 1.17 | 6.03% | 4.14% |
AI analysis
AI-generated · google/gemini-2.5-flashVaishali Pharma Limited has a market capitalization of Rs 102 Cr. The company reported revenue of Rs 102.23 Cr and a profit margin of 386.1%. Its 52-week high is Rs 13.59 and its 52-week low is Rs 4.75. The stock's price-to-earnings (PE) ratio is 24.44, and its debt-to-equity ratio is 0.24.
Positives
- +The company's debt-to-equity ratio is low at 0.24.
- +The profit margin is high at 386.1% for the fiscal year ending March 2025.
- +There is no promoter shareholding pledged (0%).
Negatives
- −Promoter holding has decreased from 56.37% in October 2019 to 30.54% in July 2026.
- −The company's stock is currently under ESM Stage 1 surveillance.
- −No quarterly results have been disclosed since March 2026.
Financial performance
For the fiscal year ending March 2025, Vaishali Pharma Limited reported an annual revenue of Rs 102.23 Cr and a net profit of Rs 0.8174 Cr. Quarterly results show revenue for March 2026 at Rs 26.93 Cr with a net profit of Rs 0.41 Cr. This follows a revenue of Rs 24.65 Cr and net profit of Rs 1.32 Cr in December 2025.
Profitability & returns
The company has a return on equity (ROE) of 6.03% and a return on capital employed (ROCE) of 8.35%. Vaishali Pharma Limited's profit margin stands at 386.1%. The earnings per share (EPS) for the fiscal year ending March 2025 was Rs 0.06.
Balance sheet
Vaishali Pharma Limited's book value is Rs 5.3 per share. The company has a debt-to-equity ratio of 0.24, indicating a low level of debt relative to equity. The company does not currently pay a dividend, with a dividend yield of 0%.
Ownership & pledges
Public shareholding stands at 69.45%. There is no pledged promoter shareholding, with promoter pledge at 0%. The number of shareholders is 26,697.
Regulatory & surveillance
Vaishali Pharma Limited is currently under ESM Stage 1 surveillance, which includes enhanced monitoring mechanisms by the exchange. This indicates specific regulatory scrutiny for the company's stock.
Data as of — price: 2026-11-07 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.